COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis | The Medical Letter Inc.
Monoclonal Antibody Authorized to Protect At-Risk People From COVID-19
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19
Plasma taurine level is linked to symptom burden and clinical outcomes in post-COVID condition
Researchers identify amino acid that may play a key role for predicting and treating long COVID
Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study
From a Grassroots Survey to Long Covid Treatment Trials
Statin Use in Relation to COVID-19 and Other Respiratory Infections: Muscle and Other Considerations
Narrative Service
Americans Don’t Get to Have the Best New COVID Drug
Further patients benefit from drug against Long COVID
Long COVID: Study Says Synbiotic Drug That Alters Gut Microbiome Relieves Multiple Symptoms
NIH Launches Trials for Long COVID Treatment Breakthroughs
Intravenous immunoglobulin as a potential treatment for long COVID
Large Review Suggests IVIG is Effective for Neurological Diseases Following COVID-19 Infection
Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review - PubMed
Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms
Clinical and CSF single-cell profiling of post-COVID-19 cognitive impairment
Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity
Long COVID Looks Like Acute Infection in the Brain
Frontiers | Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)
Study Details | Antiviral Clinical Trial for Long Covid-19 | ClinicalTrials.gov
RECOVER Clinical Trials | Home
How monoclonal antibodies lost the fight with new COVID variants
Study Shows How Paxlovid Resistance Emerges in Persistent Infections
“This type of approach helped to improve HIV drugs, and we think it’s a good way to improve antivirals against SARS-CoV-2,” says Sho Iketani, PhD, assistant professor of medical sciences at Columbia University’s Vagelos College of Physicians and Surgeons and Aaron Diamond AIDS Research Center, who co-led the research with David D. Ho, MD, the Clyde '56 and Helen Wu Professor of Medicine, professor of microbiology & immunology, and director of the Aaron Diamond AIDS Research Center, and Haitao Yang, PhD, of ShanghaiTech University.
Monoclonal antibody levels and protection from COVID-19
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro